MarketCap
Facebook
X
Telegram
Intercept Pharmaceuticals Income Statement 2022-2002 | ICPT
Brief overview of revenue and earnings at Intercept Pharmaceuticals
The conclusions below are based on five years of reported results. Intercept Pharmaceuticals reported revenue of 37.7 million dollars in 2017 and 77.2 million dollars by 2022. Overall revenue changed by +104.9%, equal to an annualized rate of about 15.4%. Revenue followed a strong upward trend without signs of stagnation.
Gross profit changed from $130 million to $76.2 million (−41.2%). Revenue outpaced cost of revenue, allowing more sales to flow into gross profit. Gross profit as a share of revenue changed from 343.8% to 98.7%. The margin decline reflects a less favorable sales-and-cost structure.
The five-year EBITDA result moved by +94.5%: from −$331 million to −$18.3 million. Changes in revenue did not translate into comparable EBITDA performance. The EBITDA share of revenue changed from −878.3% to −23.7%. The business generated more EBITDA from each unit of revenue.
The net financial result changed from −360 million dollars to −20.8 million dollars. The direction improved, yet positive earnings are still absent.
Over the period, capitalization shifted from $1.5 billion to $706 million (−51.8%). The market has not yet confirmed the improvement in fundamentals.
What the figures show
The current trajectory does not yet confirm a sustainable recovery. The financial profile benefits from an improving EBITDA margin, sales growth and improving net profitability. The weaker side of the profile includes a lower gross margin, a narrow EBITDA buffer and a weaker market valuation. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Intercept Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
706 M | 520 M | 814 M | 3.92 B | 2.87 B | 1.46 B | 2.68 B | 3.54 B | 3.24 B | 1.23 B | 215 M | - | - | - | - | - | - |
Shares |
33.8 M | 31.9 M | 33 M | 31.7 M | 28.5 M | 25.1 M | 24.7 M | 23.7 M | 20.8 M | 18 M | 6.28 M | 3.33 M | 3.33 M | - | - | - | - |
Historical Prices |
20.9 | 16.3 | 24.7 | 124 | 101 | 58.4 | 109 | 149 | 156 | 68.3 | 34.2 | - | - | - | - | - | - |
Net Income |
-20.8 M | -36.3 M | -275 M | -345 M | -309 M | -360 M | -413 M | -226 M | -283 M | -67.8 M | -43.6 M | -12.7 M | -15.1 M | -14.4 M | -13.7 M | -18.7 M | - |
Revenue |
77.2 M | 68.6 M | 234 M | 252 M | 180 M | 37.7 M | 13.8 M | 2.78 M | 1.74 M | 1.62 M | 2.45 M | 1.81 M | - | - | - | - | - |
Cost of Revenue |
984 K | 1.2 M | 2.35 M | 4.21 M | 2.52 M | 1.37 M | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | 248 M | 177 M | 130 M | 25 M | 2.78 M | - | - | - | 1.81 M | - | - | - | - | - |
Operating Income |
-18.9 M | -29.2 M | -230 M | -312 M | -285 M | -336 M | -403 M | -229 M | -113 M | - | - | - | - | - | - | - | - |
Interest Expense |
21.4 M | 54.4 M | 48.1 M | 41.1 M | 30.5 M | 29.3 M | 14.2 M | 2.73 M | 776 K | - | - | - | - | - | - | - | - |
EBITDA |
-18.3 M | -26.4 M | -227 M | -309 M | -281 M | -331 M | -399 M | -227 M | -113 M | 106 K | 201 K | 411 K | 480 K | - | - | - | - |
Operating Expenses |
- | - | - | 560 M | 465 M | 467 M | 427 M | 232 M | 115 M | 41.1 M | 21.4 M | 15.6 M | - | - | - | - | - |
General and Administrative Expenses |
176 M | 177 M | 261 M | 317 M | 255 M | 274 M | 274 M | 104 M | 34.6 M | 13.1 M | 5.18 M | 4.21 M | 3.64 M | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Intercept Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
41.8 M | 41.7 M | 41.7 M | 41.5 M | 34.3 M | 29.7 M | 29.7 M | 29.6 M | 31.7 M | 33.2 M | 33.1 M | 33 M | 33 M | 33 M | 32.6 M | 32.9 M | 32.7 M | 31.3 M | 29.8 M | 29.7 M | 29.6 M | 29.2 M | 25.3 M | 25.2 M | 25.1 M | 25 M | 24.9 M | 24.8 M | 24.7 M | 24.6 M | 24.5 M | 24.4 M | 24.2 M | 24 M | 22.2 M | 21.4 M | 21.3 M | 21 M | 19.5 M | 19.3 M | 19.2 M | 17 M | 16.6 M | 15.2 M | 3.33 M | 3.33 M | 3.33 M | 3.33 M | 3.33 M | 3.33 M | 3.33 M |
Net Income |
-2.79 M | -5.86 M | -32.1 M | - | 267 M | -7.53 M | -17.3 M | - | -3.63 M | -11.1 M | -40.4 M | -52.1 M | -66.5 M | -63.3 M | -93 M | -98.2 M | -84.8 M | -71.4 M | -90.3 M | -88 M | -64.5 M | -75.2 M | -81.6 M | -111 M | -72.6 M | -86.6 M | -89.9 M | -120 M | -88.8 M | -77.3 M | -127 M | -88.3 M | -50.9 M | -47.9 M | -39.4 M | -34.8 M | -35.8 M | 33.5 M | -258 M | -12.4 M | -31.7 M | -13.5 M | -10.2 M | -30.7 M | -5.19 M | -5.09 M | -2.68 M | -3.65 M | -2.84 M | -2.92 M | -3.33 M |
Revenue |
88.8 M | 83.7 M | 68 M | - | 77.6 M | 71.8 M | 88.6 M | - | 92.8 M | 96.6 M | 81.7 M | 83.3 M | 79.5 M | 77.2 M | 72.7 M | 71.5 M | 62 M | 66.3 M | 52.3 M | 53.3 M | 47 M | 43.6 M | 36 M | 37.7 M | 41.3 M | 30.9 M | 21 M | 13.8 M | 5.18 M | 5.52 M | 445 K | 445 K | 445 K | 445 K | 1.45 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
197 K | 185 K | 222 K | - | 424 K | 309 K | 758 K | - | 658 K | 618 K | 810 K | - | 1.83 M | 1.88 M | 852 K | - | 487 K | 677 K | 574 K | - | 519 K | 713 K | 280 K | - | 172 K | 279 K | 97 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-4.62 M | -7.12 M | -31.6 M | - | -10.1 M | -13.4 M | -10.3 M | - | -6.22 M | 760 K | -29.3 M | -40.6 M | -55.2 M | -52 M | -83.4 M | -89.3 M | -75.5 M | -63.7 M | -83.9 M | -82 M | -58.3 M | -69.8 M | -75.5 M | -105 M | -66.2 M | -80.5 M | -84 M | -114 M | -83 M | -78.1 M | -127 M | -88.9 M | -51.8 M | -48.8 M | -39.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
1.8 M | 2.81 M | 2.81 M | - | 5.24 M | 6.67 M | 6.67 M | - | 14.1 M | 12.6 M | 12.4 M | - | 12.1 M | 11.9 M | 11.8 M | - | 11.8 M | 9.88 M | 7.84 M | - | 7.67 M | 7.59 M | 7.51 M | - | 7.35 M | 7.28 M | 7.21 M | - | 7.06 M | 796 K | 726 K | - | 889 K | - | - | - | - | - | - | - | -20.6 M | -5.86 M | -3.39 M | - | -3.41 K | 117 K | 680 K | - | 2.89 K | - | - |
EBITDA |
-4.34 M | -6.94 M | -31.5 M | - | -9.65 M | -13 M | -9.9 M | - | -3.66 M | 2.51 M | -28.5 M | -40.6 M | -52.9 M | -50.5 M | -82.7 M | -89.3 M | -72.7 M | -59 M | -81.5 M | -82 M | -54.7 M | -67.3 M | -74.2 M | -105 M | -62.9 M | -78.6 M | -83.2 M | -114 M | -80.8 M | -76.6 M | -127 M | -88.9 M | -50.7 M | -48.2 M | -39.4 M | - | 210 K | 130 K | 61.7 K | - | 79.4 K | 30 K | 23 K | - | 24 K | 80 K | 74 K | - | 160 K | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 136 M | - | 105 M | 113 M | 111 M | - | 108 M | 111 M | 105 M | - | 88.2 M | 83.6 M | 128 M | - | 52.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
45.4 M | 53.3 M | 57.7 M | - | 43.3 M | 40 M | 50 M | - | 53.3 M | 57.7 M | 59.3 M | - | 70.6 M | 93.4 M | 98.6 M | - | 76.8 M | 69.7 M | 77.2 M | - | 56.8 M | 65.2 M | 62.5 M | - | 61.4 M | 66.9 M | 61.1 M | - | 44.4 M | 42.3 M | 90.4 M | - | 24.7 M | 21 M | 13.1 M | - | 9.14 M | 7.95 M | 5.65 M | 4.73 M | 3.12 M | 2.89 M | 2.4 M | 2.18 M | 991 K | 944 K | 1.06 M | 1.04 M | 1.15 M | 894 K | 1.13 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Intercept Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
